PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer

Journal of the National Cancer Institute

Volumn 107, Issue 2, 2015, Pages

  N Kirschner, Austin ^a   Wang, Jie ^a   Van Der Meer, Riet ^a   Anderson, Philip D ^c   Franco Coronel, Omar E ^a   Kushner, Max H ^d   Everett, Joel H ^a   Hameed, Omar ^a   Keeton, Erika K ^e   Ahdesmaki, Miika ^e   Grosskurth, Shaun E ^e   Huszar, Dennis ^e   Abdulkadir, Sarki A ^a,b,f  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SALISBURY UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e ASTRAZENECA   (United Kingdom)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 1208; MYC PROTEIN; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 1 INHIBITOR; PROTEIN P53; UNCLASSIFIED DRUG; AZD1208; BIPHENYL DERIVATIVE; PIM1 PROTEIN, HUMAN; PIM1 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; THIAZOLIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER INHIBITION; CANCER MODEL; CANCER PATIENT; CANCER RECURRENCE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPOXIA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION RESPONSE; RADIOSENSITIZATION; RNA SEQUENCE; TREATMENT RESPONSE; TUMOR XENOGRAFT; ALLOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL HYPOXIA; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; ONCOGENE MYC; ORAL DRUG ADMINISTRATION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ADMINISTRATION, ORAL; ALLOGRAFTS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIPHENYL COMPOUNDS; CELL HYPOXIA; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1; THIAZOLIDINES; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925545131     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju407     Document Type: Article

References (44)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011;11(1):23-34.
3. Aho TL, Sandholm J, Peltola KJ, et al. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004;571(1-3):43-49.
4. Al-Ubaidi FL, Schultz N, Egevad L, et al. Castration therapy of prostate cancer results in downregulation of HIF-1alpha levels. Int J Radiat Oncol Biol Phys. 2012;82(3):1243-1248.
5. Hittelman WN, Liao Y, Wang L, et al. Are cancer stem cells radioresistant? Future Oncol. 2010;6(10):1563-1576.
6. Aggarwal P, Vaites LP, Kim JK, et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell. 2010;18(4):329-340.
7. Anderson PD, McKissic SA, Logan M, et al. Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest. 2012;122(5):1907-1919.
8. Magnuson NS, Wang Z, Ding G, et al. Why target PIM1 for cancer diagnosis and treatment? Future Oncol. 2010;6(9):1461-1478.
9. Keeton E, McEachern K, Alimzhanov M, et al. Efficacy and biomarker modulation by AZD1208, a novel, potent and selective pan-Pim kinase inhibitor, in models of acute myeloid leukemia. In: In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. Chicago, IL, 2012: Abstract 72, p. 2796. Philadelphia (PA): AACR, Cancer Res. 2012;72(8 Suppl):Abstract nr 2796.
10. Keeton E, Palakurthi S, Alimzhanov M, et al. AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia. ASH Annual Meeting Abstracts. 2011;118(21):1540.
11. Keeton EK, McEachern K, Dillman KS, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014;123(6):905-913.
12. Ellwood-Yen K, Graeber TG, Wongvipat J, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell. 2003;4(3):223-238.
13. Watson PA, Ellwood-Yen K, King JC, et al. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res. 2005;65(24):11565-11571.
14. Hagtvet E, Roe K, Olsen DR. Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts. Radiat Oncol. 2011;6:135.
15. Kim J, Eltoum IE, Roh M, et al. Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet. 2009;5(7):e1000542.
16. R Development Core Team. R: A Language and Environment for Statistical Computing. In. Vienna, Austria: the R Foundation for Statistical Computing. ISBN: 3-900051-07-0. Available at: http://www.R-project.org; 2011.
17. TIBCO Software. In. Somerville, MA; http://spotfire.tibco.com.
18. Warnes G, Bolker B, Lumley T. gplots: Various R programming tools for plotting data. R package version 2.6.0. http://CRAN.Rproject. org/package=gplots.
19. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics. 2010;11:367.
20. Wickham H. Reshaping data with the reshape package. J Stat Software. 2007;20(12):1-20.
21. Wang J, Anderson PD, Luo W, et al. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene. 2012;31(14):1794-1803.
22. Macdonald A, Campbell DG, Toth R, et al. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol. 2006;7:1.
23. Kim J, Roh M, Abdulkadir SA. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer. 2010;10:248.
24. Chen WW, Chan DC, Donald C, et al. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 2005;3(8):443-451.
25. Zhang Y, Wang Z, Li X, et al. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene. 2008;27(35):4809-4819.
26. Zippo A, De Robertis A, Serafini R, et al. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol. 2007;9(8):932-944.
27. Holder SL, Abdulkadir SA. PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance. Curr Cancer Drug Targets. 2013;14(2):105-114.
28. Hogan C, Hutchison C, Marcar L, et al. Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J Biol Chem. 2008;283(26):18012-18023.
29. Chen J, Kobayashi M, Darmanin S, et al. Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation. Am J Pathol. 2009;175(1):400-411.
30. Kim W, Youn H, Seong KM, et al. PIM1-activated PRAS40 regulates radioresistance in non-small cell lung cancer cells through interplay with FOXO3a, 14-3-3 and protein phosphatases. Radiat Res. 2011;176(5):539-552.
31. Elkon R, Rashi-Elkeles S, Lerenthal Y, et al. Dissection of a DNA-damage-induced transcriptional network using a combination of microarrays, RNA interference and computational promoter analysis. Genome Biol. 2005;6(5):R43.
32. Chen XP, Losman JA, Cowan S, et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci U S A. 2002;99(4):2175-2180.
33. Wang J, Kim J, Roh M, et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene. 2010;29(17):2477-2487.
34. Turaka A, Buyyounouski MK, Hanlon AL, et al. Hypoxic prostate/ muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: long-term results. Int J Radiat Oncol Biol Phys. 2012;82(3):e433-e439.
35. O'Donnell KA, Yu D, Zeller KI, et al. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol. 2006;26(6):2373-2386.
36. Yu D, Cozma D, Park A, et al. Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor. Ann N Y Acad Sci. 2005;1059:145-159.
37. Schuhmacher M, Kohlhuber F, Holzel M, et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. 2001;29(2):397-406.
38. Schlosser I, Holzel M, Hoffmann R, et al. Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line. Oncogene. 2005;24(3):520-524.
39. Zeller KI, Jegga AG, Aronow BJ, et al. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003;4(10):R69.
40. Mori S, Rempel RE, Chang JT, et al. Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. Cancer Res. 2008;68(20):8525-8534.
41. Wu Q, Kirschmeier P, Hockenberry T, et al. Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells. J Biol Chem. 2002;277(39):36329-36337.
42. Scian MJ, Carchman EH, Mohanraj L, et al. Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene. 2008;27(18):2583-2593.
43. Tang X, Milyavsky M, Goldfinger N, et al. Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress. Oncogene. 2007;26(52):7302-7312.
44. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1): 11-22.